Today: 9 June 2026
Nvidia stock slips as China buyers face “pay upfront” rule for H200 AI chips
8 January 2026
1 min read

Nvidia stock slips as China buyers face “pay upfront” rule for H200 AI chips

New York, January 8, 2026, 10:31 EST — Regular session

Nvidia shares fell about 1.6% to $186.03 on Thursday after two people briefed on the matter said the chipmaker is demanding full upfront payment from Chinese customers seeking its H200, a data-center processor used to train artificial-intelligence models. The terms bar cancellations, refunds or configuration changes after an order is placed, the people said. The stock hit an intraday low of $184.73 and a high of $190.28.

The shift lands as investors start 2026 leaning again into big AI names, even as valuations and policy risk keep flashing yellow. “Investors have come into 2026 with a similar playbook to last year: Buy tech and forget about it. Rumors that the AI trade was done turned out not to be true,” Jake Dollarhide, chief executive of Longbow Asset Management, said in a note on Wednesday’s session. Reuters

China’s regulators are still deciding what strings to attach to those imports, and that uncertainty is now leaking into the commercial terms. Beijing asked some Chinese tech companies to halt H200 orders this week while it considers whether to mandate purchases of domestically made AI chips alongside Nvidia’s, The Information reported, Reuters reported on Wednesday. U.S. export licenses for the chips are still being processed with no set timeline, the report said.

The sensitivity around any Nvidia headline has been on display across the supply chain. Earlier this week, data-center cooling shares slid after CEO Jensen Huang said Nvidia’s next-generation chips were in “full production” and suggested future systems could sharply reduce cooling needs; Barclays analysts led by Julian Mitchell wrote that “given the primacy of Nvidia to the whole AI ecosystem, one should not take their comments lightly.” Reuters

Rivals are pushing their own AI hardware story at CES, but Nvidia still sets the pace for many buyers. Advanced Micro Devices’ CEO Lisa Su highlighted MI455 processors and an “enterprise” AI chip aimed at on-premise deployments, as AMD works to translate its OpenAI relationship into broader data-center wins. OpenAI President Greg Brockman said chip advances were critical to OpenAI’s computing needs, according to a Reuters report from the event. Reuters

The bigger risk is that buyers get tired of wiring cash into a deal that depends on shifting approvals, or that Beijing’s final rules curb purchases more than the market expects. A faster green light would cut the other way, but it would not erase the wider uncertainty around AI chip trade between the United States and China.

Next up, traders will look for clearer signals on Chinese approvals and export licenses, but the calendar has a hard marker: Nvidia is scheduled to report fourth-quarter fiscal 2026 results on Feb. 25, its investor site shows.

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
EV Stocks Mixed in Premarket: Rivian Rises Despite Recall as Tesla, Lucid Slip
Previous Story

EV Stocks Mixed in Premarket: Rivian Rises Despite Recall as Tesla, Lucid Slip

Broadcom stock (AVGO) slides as Nvidia’s China chip payment demand ripples through AI semiconductors
Next Story

Broadcom stock (AVGO) slides as Nvidia’s China chip payment demand ripples through AI semiconductors

Go toTop